Skip to main navigation Skip to search Skip to main content

Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities

  • Anne Knisely
  • , Yibo Dai
  • , Graham L. Barlow
  • , Sanghoon Lee
  • , Barrett Lawson
  • , Helen Clark
  • , Bryan Fellman
  • , Ying Yuan
  • , Wei Lu
  • , Idania Carolina Lubo Julio
  • , Rossana N. Lazcano
  • , Manoj Chelvanambi
  • , Brenda Melendez
  • , Bharat Singh
  • , Bhavana Singh
  • , Khalida Wani
  • , Jianfeng Chen
  • , Chih Chen Yeh
  • , Jianjun Gao
  • , Sean Barnes
  • Ou Shi, Khaja B. Khan, Alejandra G. Serrano, Lorena I. Gomez-Bolanos, Carly Bess Scalise, Samantha K. Cheung, Punashi Dutta, Sharlene Velichko, Adam C. Elnaggar, Minetta C. Liu, Roni N. Wilke, Jeffrey How, Lois M. Ramondetta, David M. Boruta, Gwyn Richardson, Aaron Shafer, Shannon N. Westin, Travis Sims, Anil K. Sood, Pedro T. Ramirez, Alexander J. Lazar, Pamela T. Soliman, Karen Lu, Cara L. Haymaker, Luisa M. Solis Soto, Jennifer A. Wargo, Rachel Grisham, Kai W. Wucherpfennig, Linghua Wang, Amir A. Jazaeri

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational value of MRD detection by second-look laparoscopy (SLL) and ctDNA at the completion of first-line therapy. Experimental Design: Patients with high-grade epithelial ovarian cancer who had a complete clinical response to first-line therapy and underwent SLL and plasma collection for ctDNA were included. Progression-free survival (PFS) and overall survival (OS) were estimated based on MRD and clinicopathologic status. Spatial transcriptomics (GeoMx and Visium) and proteomics (CODEX) profiling were performed on serial samples from select patients. Results: Forty of 95 (42.1%) patients had surgically detected MRD, which was associated with worse PFS (median PFS 7.4 vs. 23.8 months; P < 0.001) and OS (median OS 33.9 vs. not reached; P < 0.001). SLL positivity was an independent negative prognostic factor for OS (HR, 4.40; 95% confidence interval, 1.37–14.21; P ¼ 0.013) in multivariable analysis. Among 44 patients who underwent SLL and had ctDNA testing, 34% (15/44) were ctDNA-positive, which was associated with worse PFS (6.4 vs. 28.1 months; P < 0.001) and OS (32.4 months vs. not reached; P ¼ 0.008). We demonstrated the feasibility of spatial multiomics in studying MRD and their ability to provide hypothesis-generating observations, implicating the upregulation of the hypoxia signaling pathway, expression of multiple druggable targets (CDK6, GLS, MSLN, ERBB2), and immune exclusion in MRD lesions. Conclusions: Approximately half of patients in clinical re-mission after first-line therapy have assessable MRD, which can inform prognosis, therapeutic target discovery, and clinical trials.

Original languageEnglish (US)
Pages (from-to)4122-4135
Number of pages14
JournalClinical Cancer Research
Volume31
Issue number19
DOIs
StatePublished - Oct 1 2025

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities'. Together they form a unique fingerprint.

Cite this